GAMMA Investing LLC Boosts Stake in Encompass Health Co. (NYSE:EHC)

GAMMA Investing LLC grew its position in Encompass Health Co. (NYSE:EHC) by 31.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 616 shares of the company’s stock after acquiring an additional 149 shares during the quarter. GAMMA Investing LLC’s holdings in Encompass Health were worth $51,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TD Asset Management Inc grew its stake in Encompass Health by 239.6% during the fourth quarter. TD Asset Management Inc now owns 1,969,186 shares of the company’s stock worth $131,384,000 after buying an additional 1,389,275 shares during the period. 8 Knots Management LLC acquired a new stake in Encompass Health in the 4th quarter valued at $75,424,000. Norges Bank purchased a new position in Encompass Health in the fourth quarter valued at about $69,178,000. Epoch Investment Partners Inc. lifted its stake in shares of Encompass Health by 102.9% during the fourth quarter. Epoch Investment Partners Inc. now owns 1,399,341 shares of the company’s stock worth $93,364,000 after purchasing an additional 709,593 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Encompass Health by 379.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 578,349 shares of the company’s stock valued at $38,587,000 after buying an additional 457,796 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Trading Up 0.6 %

Encompass Health stock opened at $85.37 on Tuesday. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37. Encompass Health Co. has a 1 year low of $57.55 and a 1 year high of $87.94. The firm’s 50-day moving average is $84.30 and its 200-day moving average is $77.04. The company has a market cap of $8.60 billion, a P/E ratio of 23.07, a PEG ratio of 1.32 and a beta of 0.90.

Encompass Health (NYSE:EHC) last issued its earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.19. The company had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. Encompass Health’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.88 earnings per share. On average, equities analysts expect that Encompass Health Co. will post 4.1 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Monday, July 1st will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date of this dividend is Monday, July 1st. Encompass Health’s payout ratio is 16.22%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on EHC shares. Stephens reissued an “overweight” rating and set a $94.00 price target on shares of Encompass Health in a research report on Wednesday, June 5th. Mizuho upped their target price on shares of Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Royal Bank of Canada lifted their price target on shares of Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 22nd. Raymond James reissued a “strong-buy” rating and issued a $95.00 price objective (up from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Finally, Barclays boosted their price target on Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $93.29.

Insider Activity

In related news, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total value of $3,745,151.52. Following the sale, the chief executive officer now owns 554,098 shares of the company’s stock, valued at approximately $46,139,740.46. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Elissa Joy Charbonneau sold 10,000 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $85.02, for a total transaction of $850,200.00. Following the transaction, the insider now directly owns 18,594 shares of the company’s stock, valued at $1,580,861.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mark J. Tarr sold 44,976 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the sale, the chief executive officer now directly owns 554,098 shares of the company’s stock, valued at approximately $46,139,740.46. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,519 shares of company stock valued at $5,816,091. 2.10% of the stock is currently owned by company insiders.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.